Home / Sweden / Moberg Pharma AB (publ)
Moberg Pharma AB (publ)
Short position disclosed on December 19, 2019.
0.83% of the capital sold short
1 disclosing funds
125 disclosures on record
SE0003613090 ISIN code
Evolution of the disclosed total
0%0.25%0.5%0.75%1%
Oct 2025Jan 2026Apr 2026Jul 2026
March 15, 2015 today
Open positions
| Fund | Twelve months | % of capital | Over the year | Since |
|---|---|---|---|---|
| Citadel Advisors II LLC | 0.83% | unchanged | December 19, 2019 |
History of disclosures
Other companies sold short in Sweden
- Samhällsbyggnadsbolaget i Norden AB 12.26% of the capital sold short
- Elekta AB (publ) 9.63% of the capital sold short
- JM AB 7.01% of the capital sold short
- Hemnet Group AB (publ) 6.08% of the capital sold short
- Embracer Group AB 5.75% of the capital sold short
- Bonesupport Holding AB 5.67% of the capital sold short
- Truecaller AB 5.43% of the capital sold short
- Xvivo Perfusion Aktiebolag 4.91% of the capital sold short
- Tobii AB 4.34% of the capital sold short
- RaySearch Laboratories AB (publ) 4.16% of the capital sold short
- Dynavox Group AB 3.80% of the capital sold short
- Svenska Cellulosa Aktiebolaget SCA 3.77% of the capital sold short
Cite this page
The figure comes from the regulator register, not from this site. Quoting both lets your reader check it.
QuiVad, Moberg Pharma AB (publ), source Finansinspektionen, data as at December 19, 2019, https://www.quivad.com/action/moberg-pharma-ab-publ?page=3